Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL
Open Access
- 17 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Genome Medicine
- Vol. 12 (1), 1-19
- https://doi.org/10.1186/s13073-020-00724-7
Abstract
Background In cancer, normal epigenetic patterns are disturbed and contribute to gene expression changes, disease onset, and progression. The cancer epigenome is composed of the epigenetic patterns present in the tumor-initiating cell at the time of transformation, and the tumor-specific epigenetic alterations that are acquired during tumor initiation and progression. The precise dissection of these two components of the tumor epigenome will facilitate a better understanding of the biological mechanisms underlying malignant transformation. Chronic lymphocytic leukemia (CLL) originates from differentiating B cells, which undergo extensive epigenetic programming. This poses the challenge to precisely determine the epigenomic ground state of the cell-of-origin in order to identify CLL-specific epigenetic aberrations. Methods We developed a linear regression model, methylome-based cell-of-origin modeling (Methyl-COOM), to map the cell-of-origin for individual CLL patients based on the continuum of epigenomic changes during normal B cell differentiation. Results Methyl-COOM accurately maps the cell-of-origin of CLL and identifies CLL-specific aberrant DNA methylation events that are not confounded by physiologic epigenetic B cell programming. Furthermore, Methyl-COOM unmasks abnormal action of transcription factors, altered super-enhancer activities, and aberrant transcript expression in CLL. Among the aberrantly regulated transcripts were many genes that have previously been implicated in T cell biology. Flow cytometry analysis of these markers confirmed their aberrant expression on malignant B cells at the protein level. Conclusions Methyl-COOM analysis of CLL identified disease-specific aberrant gene regulation. The aberrantly expressed genes identified in this study might play a role in immune-evasion in CLL and might serve as novel targets for immunotherapy approaches. In summary, we propose a novel framework for in silico modeling of reference DNA methylomes and for the identification of cancer-specific epigenetic changes, a concept that can be broadly applied to other human malignancies.Funding Information
- Bundesministerium für Bildung und Forschung (031L0076A)
- Deutsche Krebshilfe (DKH 70113869)
This publication has 93 references indexed in Scilit:
- A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation dataBioinformatics, 2012
- The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor SuppressorCell, 2012
- Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney TumorCell, 2012
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- Transcription Factor AP1 Potentiates Chromatin Accessibility and Glucocorticoid Receptor BindingMolecular Cell, 2011
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse ModelCancer Cell, 2009
- Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformationNature, 2008
- Bmi1 is expressed in vivo in intestinal stem cellsNature Genetics, 2008